frontiers | Frontiers in Pharmacology

TYPE Correction
PUBLISHED 01 March 2023
DOI 10.3389/fphar.2023.1169734

OPEN ACCESS

EDITED AND REVIEWED BY
Silvia Nistri,
University of Florence, Italy

*CORRESPONDENCE
Shuyu Yang,
ysyxmu@163.com

SPECIALTY SECTION
This article was submitted to Cardiovascular and Smooth Muscle Pharmacology, a section of the journal Frontiers in Pharmacology

RECEIVED 20 February 2023
ACCEPTED 21 February 2023
PUBLISHED 01 March 2023

CITATION
Han J, Zhang Z, Zhang Z and Yang S (2023), Corrigendum: Artemisinin relieves myocardial ischemia-reperfusion injury *via* modulating miR-29b-3p and hemicentin 1.
Front. Pharmacol. 14:1169734.
doi: 10.3389/fphar.2023.1169734

Corrigendum: Artemisinin relieves myocardial ischemia-reperfusion injury *via* modulating miR-29b-3p and hemicentin 1

Junyu Han[1], Ziguan Zhang[1], Zhonghe Zhang[1] and Shuyu Yang[2]*

[1]Department of Cardiology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China, [2]Xiamen Diabetes Institute, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China

KEYWORDS

myocardial ischemia-reperfusion, artemisinin, high throughput sequencing, miR-29b-3p, hemicentin 1, oxidative stress

A Corrigendum on
Artemisinin relieves myocardial ischemia-reperfusion injury *via* modulating miR-29b-3p and hemicentin 1

by Han J, Zhang Z, Zhang Z and Yang S (2022). Front. Pharmacol. 13:918966. doi: 10.3389/fphar.2022.918966

In the published article, there was an error in **Figure 6** as published. The corrected Figure 6 and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

10.3389/fphar.2023.1169734



FIGURE 6
ARS suppresses myocardial I/R injury through regulating miR-29b-3p/HMCN1 in vivo.